Chinese medical portal censored after doubting herbal 'Covid remedy'

Chinese medical portal censored after doubting herbal 'Covid remedy'

DXY's article was part of a wave of reports that caused shares in Lianhua Qingwen's producer -- one of China's largest traditional medicine companies -- to plunge
DXY's article was part of a wave of reports that caused shares in Lianhua Qingwen's producer -- one of China's largest traditional medicine companies -- to plunge. Photo: STR / AFP/File
Source: AFP

New feature: Check out news exactly for YOU ➡️ find “Recommended for you” block and enjoy!

A popular Chinese medical information site has been censored by authorities for "violation of relevant laws and regulations", months after its criticism of a government-backed herbal Covid-19 treatment sent shares in a pharmaceutical giant tumbling.

DXY, which counts tech giant Tencent among its investors and runs a host of health-related services, previously questioned the value of Lianhua Qingwen, a herbal remedy marketed for fever and sore throats, as a Covid-19 treatment.

China approved the concoction -- made up of ingredients like honeysuckle and apricot seeds -- as a Covid-19 treatment in 2020, and it was distributed to Shanghai residents during the city's outbreak this year.

DXY's article was part of a wave of reports that caused shares in Lianhua Qingwen's producer -- one of China's largest traditional medicine companies -- to plunge.

Read also

China's ex-Covid patients live under 'dark shadow' of stigma

The website has now been banned from posting on at least five of its Weibo social media accounts, with a notice at the top of its official page saying that due to "violation of relevant laws and regulations, this user is currently prohibited from posting".

DXY's official WeChat accounts, which typically publish multiple articles a day on medical topics, have not been updated since Monday.

PAY ATTENTION: Follow Briefly News on Twitter and never miss the hottest topics! Find us at @brieflyza!

The Weibo notice did not specify which regulations had been violated by DXY, which did not immediately respond to AFP's request for comment.

The Chinese government has increasingly promoted traditional medicine at home and abroad in recent years, often with nationalistic undertones.

DXY's coverage prompted criticism that it was targeting traditional Chinese medicine (TCM) in order to promote Western pharmaceuticals.

The United States and other countries have warned there is no evidence Lianhua Qingwen works to prevent or cure Covid-19, even as it has increasingly been promoted by government authorities in China and Hong Kong.

Read also

Tonnes of fruit stranded in EU, S.Africa battle of oranges

The US Food and Drug Administration has said it has not approved Lianhua Qingwen and that coronavirus-related claims about it were "not supported by competent and reliable scientific evidence".

Beijing issued its first white paper on TCM in 2016, laying out plans to build medicine centres and dispatch practitioners to developing countries in Africa and Southeast Asia.

President Xi Jinping has described TCM as a "treasure of Chinese civilisation" and has said that it should be given as much weight as other treatments.

Beijing's National Health Commission has also dispatched TCM practitioners as part of its medical reinforcement teams sent to fight Covid-19 outbreaks across the country.

New feature: check out news exactly for YOU ➡️ find "Recommended for you" block and enjoy!

Source: AFP

Authors:
AFP avatar

AFP AFP text, photo, graphic, audio or video material shall not be published, broadcast, rewritten for broadcast or publication or redistributed directly or indirectly in any medium. AFP news material may not be stored in whole or in part in a computer or otherwise except for personal and non-commercial use. AFP will not be held liable for any delays, inaccuracies, errors or omissions in any AFP news material or in transmission or delivery of all or any part thereof or for any damages whatsoever. As a newswire service, AFP does not obtain releases from subjects, individuals, groups or entities contained in its photographs, videos, graphics or quoted in its texts. Further, no clearance is obtained from the owners of any trademarks or copyrighted materials whose marks and materials are included in AFP material. Therefore you will be solely responsible for obtaining any and all necessary releases from whatever individuals and/or entities necessary for any uses of AFP material.